Stock Research for ANIP


Featured Broker: Ally Invest

Get the due diligence for another stock.


ANIP Stock Chart & Research Data

The ANIP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ANIP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ANIP Due diligence Resources & Stock Charts

The ANIP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ANIP Detailed Price Forecast - CNN Money CNN View ANIP Detailed Summary - Google Finance
Yahoo View ANIP Detailed Summary - Yahoo! Finance Zacks View ANIP Stock Research & Analysis -

Stock Analysis

TradeIdeas View ANIP Trends & Analysis - Trade-Ideas Barrons View ANIP Major Holders - Barrons
NASDAQ View ANIP Call Transcripts - NASDAQ Seeking View ANIP Breaking News & Analysis - Seeking Alpha
Spotlight View ANIP Annual Report - OTC Report View ANIP OTC Short Report -
TradeKing View ANIP Fundamentals - TradeKing Charts View ANIP SEC Filings - Bar Chart
WSJ View Historical Prices for ANIP - The WSJ Morningstar View Performance/Total Return for ANIP - Morningstar
MarketWatch View the Analyst Estimates for ANIP - MarketWatch CNBC View the Earnings History for ANIP - CNBC
StockMarketWatch View the ANIP Earnings - StockMarketWatch MacroAxis View ANIP Buy or Sell Recommendations - MacroAxis
Bullish View the ANIP Bullish Patterns - American Bulls Short Pains View ANIP Short Pain Metrics -

Social Media Mentions

StockTwits View ANIP Stock Mentions - StockTwits PennyStocks View ANIP Stock Mentions - PennyStockTweets
Twitter View ANIP Stock Mentions - Twitter Invest Hub View ANIP Investment Forum News - Investor Hub
Yahoo View ANIP Stock Mentions - Yahoo! Message Board Seeking Alpha View ANIP Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ANIP - Insider Cow View Insider Transactions for ANIP - Insider Cow
CNBC View ANIP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ANIP - OTC Markets
Yahoo View Insider Transactions for ANIP - Yahoo! Finance NASDAQ View Institutional Holdings for ANIP - NASDAQ

Stock Charts

FinViz View ANIP Stock Insight & Charts - StockCharts View ANIP Investment Charts -
BarChart View ANIP Stock Overview & Charts - BarChart Trading View View ANIP User Generated Charts - Trading View

Latest Financial News for ANIP

Analysis: Positioning to Benefit within Clovis Oncology, Destination Maternity, MSG Networks, Lindblad Expeditions, NetScout, and ANI Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Thursday October 18, 2018

NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

ANI Announces Launch of Authorized Generic of Brethine®
Posted on Tuesday October 16, 2018

BAUDETTE, Minn., Oct. 16, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine®. The current annual U.S. market for this product is approximately $11 million, according to Iqvia. Prior to ANI's launch there was only one supplier of the product in the U.S. market. ANI acquired the NDA for Brethine® (terbutaline sulfate) tablets in December 2016. Arthur S. Przybyl, ANI's President and CEO stated, "ANI continues to successfully execute on our strategy of re-commercializing products from our portfolio of acquired discontinued ANDAs and NDAs.

ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets
Posted on Thursday October 04, 2018

BAUDETTE, Minn., Oct. 4, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT®.  The current annual U.S. market for this product is approximately $20 million, according to Iqvia/IMS Health. Arthur S. Przybyl, ANI's President and CEO stated, "We are pleased to announce the launch of the authorized generic of our brand product Atacand HCT®. Atacand HCT® is indicated for the treatment of hypertension.

ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
Posted on Thursday September 27, 2018

BAUDETTE, Minn., Sept. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (ANIP) announced today that it will present on Wednesday, October 3, 2018 at 2:50 PM ET at the Cantor Fitzgerald Global Healthcare Conference in New York City. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at and will be archived and available through the link through January 1, 2019. ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.